MacroGenics argues that margetuximab works by tweaking the “Fc” part of Herceptin – the tail of the ‘Y’ shaped antibody – so that it interacts more efficiently with the immune system ...

MacroGenics has altered the “Fc” part of the antibody – the tail of the ‘Y’-shaped molecule – so that it interacts more efficiently with the immune system when engaged with a cancer cell.

MacroGenics' valuation has declined due to ... like the CD123-targeted DART molecule MGD024, the B7-H3 novel ADC MGC026 in phase 1 study, and MGC028, an ADAM9 ADC set to move into the clinic ...

MacroGenics has a strong cash position ... three molecules with our three core platforms, our FC engineered, our DART bispecific and our ADC platform are being pursued for treatments for various ...